Karyopharm approval label for Xpovio 'compelling,' says H.C. Wainwright
Karyopharm Therapeutics on Wednesday, three days before the action date date, announced that the FDA granted accelerated approval for Xpovio n relapsed or refractory multiple myeloma patients who have received at least four prior therapies and whose disease was refractory after at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, H.C. Wainwright analyst Edward White tells investors in a research note. Further, there is not a black box warning or contraindications in the Xpovio label, adds the analyst. He finds the label "compelling and inline with expectations." White estimates Xpovio in the penta-refractory setting will have sales of $5.5less than this year rising to $123.8M in 2026. He keeps a Buy rating on Karyopharm Therapeutics with a $32 price target.